DonaldZozMDFCCP
Pulmonology • Lebanon, OHInterstitial Lung Diseases
Sr. Clinical Program Leader - IPF/ILD Boehringer Ingelheim
Dr. Zoz is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
Remote
Lebanon, OH 45036- Is this information wrong?
Education & Training
Vanderbilt University Medical CenterFellowship, Pulmonary Disease and Critical Care Medicine, 2008 - 2011
Ohio State University HospitalResidency, Internal Medicine, 2005 - 2008- Ohio State University College of MedicineClass of 2005
Certifications & Licensure
OH State Medical License 2006 - 2025
TN State Medical License 2008 - 2011- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2013
Clinical Trials
- Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) Start of enrollment: 2013 Jan 31
- Efficacy, Pharmacokinetics, and Safety of Presatovir in Hospitalized Adults With Respiratory Syncytial Virus (RSV) Infection Start of enrollment: 2014 Jun 09
- Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment Start of enrollment: 2016 Jun 09
- Join now to see all
Publications & Presentations
PubMed
- Clinical trial simulations in pulmonary fibrosis: patient-focused insights and adaptations.Steve Jones, Maxine Flewett, Ron Flewett, Sharon Lee, Bill Vick, Milla Thompson, Sabine Pinnetti, Donald F Zoz, Anna-Maria Hoffmann-Vold, Michael Kreuter, Toby M Maher> ;ERJ Open Research. 2023 May 1
- 3 citationsUnderstanding diagnostic pathways in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: A retrospective cohort study.Shervin Assassi, Nan Shao, Ziwei Yin, Elizabeth R Volkmann, Donald F Zoz, Thomas B Leonard> ;Medicine. 2022 Aug 12
- 1 citationsPlain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosis.Luca Richeldi, Arata Azuma, Vincent Cottin, Christian Hesslinger, Susanne Stowasser, Claudia Valenzuela, Marlies S Wijsenbeek, Donald F Zoz, Florian Voss, Toby M Maher> ;Journal of Comparative Effectiveness Research. 2022 Dec 20
- Join now to see all
Press Mentions
First Patient Enrolled in Phase 3 Trial Testing BI 1015550October 28th, 2022- Boehringer Enrols First Subject in Idiopathic Pulmonary Fibrosis TrialOctober 27th, 2022
Systemic Sclerosis (Scleroderma): Nintedanib Slowed Loss of Pulmonary FunctionMay 30th, 2019
Professional Memberships
- Member
- Fellow
Industry Relationships
- Director - Clinical Development & Medical Affairs - Respiratory IPF/ILD, Boehringer Ingelheim Pharmaceuticals, Inc2017 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
